Literature DB >> 29357202

Framingham Stroke Risk Profile is related to cerebral small vessel disease progression and lower cognitive performance in patients with hypertension.

Renske Uiterwijk1,2, Julie Staals1,3, Marjolein Huijts4, Peter W de Leeuw3,5,6, Abraham A Kroon3,5, Robert J van Oostenbrugge1,2,3.   

Abstract

The Framingham Stroke Risk Profile (FSRP) was developed to predict clinical stroke. We investigated if FSRP is associated with more "silent" effects of cerebrovascular disease, namely progression of cerebral small vessel disease (cSVD)-related brain damage and cognitive performance in hypertensive patients. Ninety patients with essential hypertension underwent a brain MRI scan and FSRP assessment at baseline, and a second brain MRI scan and neuropsychological assessment at 9-year follow-up. We visually rated progression of cSVD-related MRI markers. FSRP was associated with progressive periventricular white matter hyperintensities (P = .017) and new microbleeds (P = .031), but not after correction for the FSRP age component. FSRP was associated with lower overall cognitive performance (P < .001) and this remained significant after correction for the FSRP age component. A vascular risk score might be useful in predicting progression of cSVD-related brain damage or future cognitive performance in hypertensive patients. Age seems to be the most important component in FSRP. ©2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  Framingham stroke risk profile; cerebral small vessel disease; cognition; hypertension

Mesh:

Year:  2018        PMID: 29357202      PMCID: PMC8031354          DOI: 10.1111/jch.13175

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  33 in total

1.  [The Dutch Reading Test for Adults: a measure of premorbid intelligence level].

Authors:  B Schmand; D Bakker; R Saan; J Louman
Journal:  Tijdschr Gerontol Geriatr       Date:  1991-02

Review 2.  Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective.

Authors:  Matthew Baumgart; Heather M Snyder; Maria C Carrillo; Sam Fazio; Hye Kim; Harry Johns
Journal:  Alzheimers Dement       Date:  2015-06-01       Impact factor: 21.566

Review 3.  White matter hyperintensities, cognitive impairment and dementia: an update.

Authors:  Niels D Prins; Philip Scheltens
Journal:  Nat Rev Neurol       Date:  2015-02-17       Impact factor: 42.937

4.  Diagnostic value of the Rotterdam-CAMCOG in post-stroke dementia.

Authors:  I de Koning; F van Kooten; P J Koudstaal; D W J Dippel
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-02       Impact factor: 10.154

Review 5.  Longitudinal change of small-vessel disease-related brain abnormalities.

Authors:  Reinhold Schmidt; Stephan Seiler; Marisa Loitfelder
Journal:  J Cereb Blood Flow Metab       Date:  2016-01       Impact factor: 6.200

6.  Measuring progression of cerebral white matter lesions on MRI: visual rating and volumetrics.

Authors:  N D Prins; E C W van Straaten; E J van Dijk; M Simoni; R A van Schijndel; H A Vrooman; P J Koudstaal; P Scheltens; M M B Breteler; F Barkhof
Journal:  Neurology       Date:  2004-05-11       Impact factor: 9.910

Review 7.  Hypertension and cerebrovascular damage.

Authors:  Franco Veglio; Cristina Paglieri; Franco Rabbia; Daniela Bisbocci; Mauro Bergui; Paolo Cerrato
Journal:  Atherosclerosis       Date:  2008-11-05       Impact factor: 5.162

8.  Stroke risk profile predicts white matter hyperintensity volume: the Framingham Study.

Authors:  Tom Jeerakathil; Philip A Wolf; Alexa Beiser; Joseph Massaro; Sudha Seshadri; Ralph B D'Agostino; Charles DeCarli
Journal:  Stroke       Date:  2004-06-24       Impact factor: 7.914

Review 9.  Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging.

Authors:  Joanna M Wardlaw; Colin Smith; Martin Dichgans
Journal:  Lancet Neurol       Date:  2013-05       Impact factor: 44.182

10.  Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration.

Authors:  Joanna M Wardlaw; Eric E Smith; Geert J Biessels; Charlotte Cordonnier; Franz Fazekas; Richard Frayne; Richard I Lindley; John T O'Brien; Frederik Barkhof; Oscar R Benavente; Sandra E Black; Carol Brayne; Monique Breteler; Hugues Chabriat; Charles Decarli; Frank-Erik de Leeuw; Fergus Doubal; Marco Duering; Nick C Fox; Steven Greenberg; Vladimir Hachinski; Ingo Kilimann; Vincent Mok; Robert van Oostenbrugge; Leonardo Pantoni; Oliver Speck; Blossom C M Stephan; Stefan Teipel; Anand Viswanathan; David Werring; Christopher Chen; Colin Smith; Mark van Buchem; Bo Norrving; Philip B Gorelick; Martin Dichgans
Journal:  Lancet Neurol       Date:  2013-08       Impact factor: 44.182

View more
  11 in total

Review 1.  The importance of comorbidities in ischemic stroke: Impact of hypertension on the cerebral circulation.

Authors:  Marilyn J Cipolla; David S Liebeskind; Siu-Lung Chan
Journal:  J Cereb Blood Flow Metab       Date:  2018-09-10       Impact factor: 6.200

2.  Revised Framingham Stroke Risk Profile: Association with Cognitive Status and MRI-Derived Volumetric Measures.

Authors:  Isabelle Pelcher; Christian Puzo; Yorghos Tripodis; Hugo J Aparicio; Eric G Steinberg; Alyssa Phelps; Brett Martin; Joseph N Palmisano; Elizabeth Vassey; Cutter Lindbergh; Ann C McKee; Thor D Stein; Ronald J Killiany; Rhoda Au; Neil W Kowall; Robert A Stern; Jesse Mez; Michael L Alosco
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

3.  Vascular burden and APOE ε4 are associated with white matter microstructural decline in cognitively normal older adults.

Authors:  Owen A Williams; Yang An; Lori Beason-Held; Yuankai Huo; Luigi Ferrucci; Bennett A Landman; Susan M Resnick
Journal:  Neuroimage       Date:  2018-12-15       Impact factor: 6.556

4.  Study on the Interaction between the Characteristics of Retinal Microangiopathy and Risk Factors for Cerebral Small Vessel Disease.

Authors:  Qian Tang; Yanli Zhang; Zhengfang Yang; Siou Li; Meini Wu; Yongming Guo; Weina Zhao; Changhao Yin
Journal:  Contrast Media Mol Imaging       Date:  2022-06-09       Impact factor: 3.009

5.  Framingham Stroke Risk Profile is related to cerebral small vessel disease progression and lower cognitive performance in patients with hypertension.

Authors:  Renske Uiterwijk; Julie Staals; Marjolein Huijts; Peter W de Leeuw; Abraham A Kroon; Robert J van Oostenbrugge
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-01-22       Impact factor: 3.738

6.  Searching cerebrovascular risk indicators for hypertensive patients: Is Framingham Stroke Risk Profile "the magic bullet"?

Authors:  Andrea Semplicini
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-01-22       Impact factor: 3.738

7.  Breast Arterial Calcification Is Not Associated with Mild Cognitive Impairment or Incident All-Cause Dementia Among Postmenopausal Women: The MINERVA Study.

Authors:  Carlos Iribarren; Malini Chandra; Sabee Molloi; Gabriela Sanchez; Fatemeh Azamian-Bidgoli; Hyo-Min Cho; Huanjun Ding; Kristine Yaffe
Journal:  J Womens Health (Larchmt)       Date:  2020-12-07       Impact factor: 3.017

8.  Plasma brain natriuretic peptide is a biomarker for screening ischemic cerebral small vessel disease in patients with hypertension.

Authors:  Weimin Wei; Yan Chen; Da Lei; Yanan Zhang; Xiuhong Weng; Yuliang Zhou; Li Zhang
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

9.  The value of mobile magnetic resonance imaging in early warning for stroke: A prospective case-control study.

Authors:  Miaomiao Liu; Qingyang Li; Guoqiang Chen; Ning Su; Maorong Zhou; Xiaolin Liu; Kai Sun
Journal:  Front Neurosci       Date:  2022-08-12       Impact factor: 5.152

10.  Association of midlife stroke risk with structural brain integrity and memory performance at older ages: a longitudinal cohort study.

Authors:  Enikő Zsoldos; Abda Mahmood; Nicola Filippini; Sana Suri; Verena Heise; Ludovica Griffanti; Clare E Mackay; Archana Singh-Manoux; Mika Kivimäki; Klaus P Ebmeier
Journal:  Brain Commun       Date:  2020-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.